Grifols (GRFS) Change in Inventory (2010 - 2020)
Grifols (GRFS) reported Change in Inventory of -$82.4 million for Q1 2020, up 45.15% on a YoY basis from -$56.8 million in Q2 2019, and up 70.56% quarter-over-quarter from -$280.1 million in Q4 2019.
Grifols (GRFS) Change in Inventory (2010 - 2020) Analysis & Trends
Grifols has reported Change in Inventory for 10 years, with the latest figure at -$82.4 million in Q1 2020.
- For the quarter ending Q1 2020, Change in Inventory rose 45.15% year-over-year to -$82.4 million; the trailing twelve-month figure through Mar 2020 stood at -$305.9 million (down 187.56% YoY), and the FY2025 full-year result was -$112.9 million, down 506.4% from the prior year.
- Change in Inventory for Q1 2020 stood at -$82.4 million, up from -$280.1 million in the prior quarter.
- The five-year high for Change in Inventory was $206.9 million in Q4 2018, with the low at -$301.5 million in Q3 2016.
- Historically, Change in Inventory has averaged -$54.9 million across 5 years, with a median of -$29.6 million in 2016.
- Annual changes were most pronounced in 2017 — Change in Inventory surged 530.79% — and 2018, when it tumbled 5685.14%.
- Grifols' Change in Inventory stood at -$29.6 million in 2016, then surged by 530.79% to $127.6 million in 2017, then soared by 62.12% to $206.9 million in 2018, then tumbled by 235.34% to -$280.1 million in 2019, then jumped by 70.56% to -$82.4 million in 2020.
- The last three Change in Inventory figures came in at -$82.4 million (Q1 2020), -$280.1 million (Q4 2019), and -$150.3 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 431.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 184.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -14.00 Mn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -82.45 Mn |
| Mar 31, 2020 | -82.45 Mn |
| Dec 31, 2019 | -280.06 Mn |
| Dec 31, 2019 | -280.06 Mn |
| Mar 31, 2019 | -150.30 Mn |
| Mar 31, 2019 | -150.30 Mn |
| Dec 31, 2018 | 206.94 Mn |
| Dec 31, 2018 | 206.94 Mn |
| Jun 30, 2018 | -266.03 Mn |
| Jun 30, 2018 | -266.03 Mn |
| Mar 31, 2018 | 103.03 Mn |
| Mar 31, 2018 | 103.03 Mn |
| Dec 31, 2017 | 127.65 Mn |
| Dec 31, 2017 | 127.65 Mn |
| Jun 30, 2017 | 4.76 Mn |
| Jun 30, 2017 | 4.76 Mn |
| Mar 31, 2017 | 63.80 Mn |
| Mar 31, 2017 | 63.80 Mn |
| Dec 31, 2016 | -29.63 Mn |
| Dec 31, 2016 | -29.63 Mn |